Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2020

View Archived Issues

Gaining insights into loss of function

Mice and men and estrogen

TLC submits IND application in Taiwan for inhalable liposomal hydroxychloroquine for COVID-19

New model displays transition to cardiac failure and reverse modeling

First patient dosed in phase I/II study of PRGN-2009

Positive data presented from phase II study of F-351 in China

Sichuan Kelun-Biotech Biopharmaceutical synthesizes new camptothecin derivatives

New CACNA2D ligands discovered at Sichuan Haisco Pharmaceutical

Gargamel (Zhuhai) Biotech discovers JAK-1 inhibitors

New MAP2K1 inhibitors patented by Betta Pharmaceuticals

CSPC Zhongqi Pharmaceutical Technology describes PROTAC BRD4 degradation inducers

CytoDyn presents update on its HIV programs

Dosing initiates in phase Ib study of plonmarlimab in Chinese patients with RA

Discovery of novel MAbs as promising COVID-19 immunotherapies

Neurotransmitter-derived synthetic lipids for delivery of BBB-impermeable cargos into the brain

Microfibrillar-associated glycoprotein 4 is a biomarker of alcoholic liver disease-related fibrosis

Targeting nuclear transport protein could lead to opioid alternatives

Improved oxygenation observed in COVID-19 patients treated with icatibant

UNITY presents 12-week data from phase II study of UBX-0101 in painful osteoarthritis of the knee

Interim analysis data from ODYSSEY study of tradipitant in COVID-19 pneumonia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...